Saptalis Pharmaceuticals LLC has launched Cyclosporine Ophthalmic Emulsion 0.05%, a preservative-free treatment designed to increase tear production for dry eye disease, available in single-use vials. This release is part of a broader strategy to enhance their portfolio, which now includes several other products, such as Tofacitinib Oral Solution and Hydroxyzine HCl Oral Solution, aimed at addressing various autoimmune, dermatological, and psychiatric conditions. The company emphasizes its commitment to U.S.-based manufacturing and the development of innovative therapies to meet unmet medical needs. All products require a prescription and healthcare provider supervision.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.businesswire.com/news/home/20260615002347/en/Saptalis-Pharmaceuticals-Launches-Cyclosporine-Ophthalmic-Emulsion-0.05-and-Expands-Product-Portfolio
